HUTCHMED shares rise as lung cancer drug trial hits key targets
Yahoo Finance · Aug 17, 2026 · HCM (HCM)
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in...
Not investment advice. Cached headline, not a full reprint.